Charles Schwab’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Charles Schwab’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,423	Closed	-$150K	–	3209
2019 Q2	$150K	Sell	22,423 -12,667	-36%	-$48.2K	﹤0.01%	3107
2019 Q1	$125K	Buy	35,090 +740	+2%	+$4.02K	﹤0.01%	3078
2018 Q4	$137K	Sell	34,350 -3,092	-8%	-$39.5K	﹤0.01%	3065
2018 Q3	$740K	Buy	37,442 +2,371	+7%	+$59.9K	﹤0.01%	2709
2018 Q2	$1.11M	Buy	35,071 +20,137	+135%	+$725K	﹤0.01%	2559
2018 Q1	$553K	Buy	14,934 +5,410	+57%	+$356K	﹤0.01%	2706
2017 Q4	$753K	Buy	+9,524	New	+$705K	﹤0.01%	2609

Other funds holding MLNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Charles Schwab's MLNT Position: Q3 2019 in Review

Charles Schwab sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 22,423 shares — an estimated $150K sold.

Charles Schwab first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $1.11M in Q2 2018. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Charles Schwab reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Charles Schwab sold 22,423 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $150K.
Charles Schwab first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Charles Schwab's Melinta Therapeutics, Inc. Common Stock position peaked at $1.11M in Q2 2018.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Charles Schwab's 13F filing for Q3 2019, filed 8 Nov 2019.